EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.
April F Eichler, Kristopher T Kahle, Daphne L Wang...
https://pubmed.ncbi.nlm.nih.gov/20627894/Actively Recruiting
Led by Alpha Biopharma (Jiangsu) Co., Ltd. · Updated on 2026-06-22
42
Participants Needed
5
Research Sites
20 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of combining Zorifertinib with Osimertinib for people who have advanced Non-Small Cell Lung Cancer NSCLC that has spread to the membranes around the brain and spinal cord, known as leptomeningeal metastases. This study focuses on patients who have already been treated with Osimertinib but experienced progression in the meningeal area. The trial is a Phase 1 study designed to find the recommended dose and further assess safety and treatment response. All participants will receive both Zorifertinib and Osimertinib. Zorifertinib is given orally twice daily at increasing doses starting at 100 mg, while Osimertinib is taken once daily at a fixed dose of 80 mg. The study has two parts Part A involves dose escalation to identify the best dose for further use, and Part B expands the number of participants receiving the recommended dose to evaluate safety, effectiveness, and how the body processes the drugs. Treatment continues until the cancer worsens, side effects become unacceptable, or other stopping criteria are met. Participants will be monitored through regular assessments including neurological exams, brain and spinal imaging, and cerebrospinal fluid tests. Researchers will measure dose-limiting toxicities during the first 21 days, track adverse events and serious side effects for up to 12 months, and evaluate tumor responses using standardized criteria. Outcomes such as progression-free survival, response rates in the brain and overall tumors, and changes in neurological function will be closely followed. The study may last until September 2028, with safety and effectiveness data collected throughout treatment.
CONDITIONS
Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
J
John Ge, M.D
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Alpha Biopharma (Jiangsu) Co., Ltd.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - Up to 12 months or until discontinuation
Participants receive oral Zorifertinib twice daily with dose escalation and fixed-dose Osimertinib once daily. Treatment continues until disease progression, unacceptable side effects, or other stopping criteria.
Regular visits for safety and response assessments during treatment cycles
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
April F Eichler, Kristopher T Kahle, Daphne L Wang...
https://pubmed.ncbi.nlm.nih.gov/20627894/Peter Ballard, James W T Yates, Zhenfan Yang...
https://pubmed.ncbi.nlm.nih.gov/27435396/Glenwood Goss, Chun-Ming Tsai, Frances A Shepherd...
https://pubmed.ncbi.nlm.nih.gov/27751847/E Le Rhun, M Weller, D Brandsma...
https://pubmed.ncbi.nlm.nih.gov/28881917/C C Schag, R L Heinrich, P A Ganz
https://pubmed.ncbi.nlm.nih.gov/6699671/Terri S Armstrong, Marlene Z Cohen, Lillian Eriksen...
https://pubmed.ncbi.nlm.nih.gov/15897941/Antonio M P Omuro, Mark G Kris, Vincent A Miller...
https://pubmed.ncbi.nlm.nih.gov/15844174/David M Jackman, Alison J Holmes, Neal Lindeman...
https://pubmed.ncbi.nlm.nih.gov/16983123/Toshihiko Iuchi, Masato Shingyoji, Meiji Itakura...
https://pubmed.ncbi.nlm.nih.gov/25336382/Ana Aparicio, Marc C Chamberlain
https://pubmed.ncbi.nlm.nih.gov/11937001/Alpha Biopharma (Jiangsu) Co., Ltd.
Lead Sponsor